MELBOURNE, Australia--Australian biotechnology firm CSL Ltd. (CSL.AU) has struck a deal to buy control of a plasma-derived therapies manufacturer in China from Humanwell Healthcare Group Co.
"But given the balance sheet, it's not a large acquisition for CSL and likely won't have a material impact on earnings for a number of years." Demand for immunoglobulin is expected to grow rapidly.